Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy.

[1]  J. Golledge,et al.  Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study. , 2009, Journal of vascular surgery.

[2]  S. Devaraj,et al.  Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes , 2009, Diabetologia.

[3]  M. Cooper,et al.  RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. , 2009, Journal of the American Society of Nephrology : JASN.

[4]  L. Audoly,et al.  Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE , 2007, Nature Immunology.

[5]  P. Nawroth,et al.  Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes , 2007, Cardiovascular diabetology.

[6]  I. Lednev,et al.  Hexameric Calgranulin C (S100A12) Binds to the Receptor for Advanced Glycated End Products (RAGE) Using Symmetric Hydrophobic Target-binding Patches* , 2006, Journal of Biological Chemistry.

[7]  C. Heizmann,et al.  Pathologies involving the S100 proteins and RAGE. , 2007, Sub-cellular biochemistry.

[8]  L. Leng,et al.  Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes , 2006, Diabetologia.

[9]  E. Abraham,et al.  High mobility group box 1 protein interacts with multiple Toll-like receptors. , 2006, American journal of physiology. Cell physiology.

[10]  D. Stern,et al.  Understanding RAGE, the receptor for advanced glycation end products , 2005, Journal of Molecular Medicine.

[11]  Merlin C. Thomas,et al.  Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.

[12]  G. Jerums,et al.  The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[14]  V. D’Agati,et al.  RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.

[15]  Merlin C. Thomas,et al.  Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. , 2002, Diabetes.

[16]  J. Nagy,et al.  N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  S. Takasawa,et al.  Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. , 2001, The Journal of clinical investigation.

[18]  G. Jerums,et al.  Renoprotective effects of a novel inhibitor of advanced glycation , 2001, Diabetologia.

[19]  A. Dawnay,et al.  Mass spectrometric monitoring of albumin in uremia. , 2000, Kidney international.

[20]  T. Miyata,et al.  Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. , 2000, Journal of the American Society of Nephrology : JASN.

[21]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[22]  S. Genuth,et al.  Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Contro , 1999, Diabetes.

[23]  J. Baynes,et al.  Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.

[24]  E. Schleicher,et al.  Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. , 1997, The Journal of clinical investigation.

[25]  J. Chen,et al.  The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.

[26]  F N Ziyadeh,et al.  Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy. , 1995, The Journal of clinical investigation.

[27]  A. McElduff,et al.  Diabetes Control and Complications Trial , 1993 .

[28]  G. Jerums,et al.  Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat , 1991, Diabetes.

[29]  J. Baynes,et al.  Nonenzymatic Glucosylation of Serum Proteins in Diabetes Mellitus , 1979, Diabetes.

[30]  L. Maillard,et al.  Action des acides amines sur les sucres : formation des melanoidines par voie methodique , 1912 .